BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
Recs
Well positioned in an industry that is poised for a dramatic acceleration in growth as predictive medicine and molecular diagnostics begin to gain traction. Recent weakness primarily driven by shorter term concerns present a great entry point for longer term investors. While still burning cash (although moderatimg), a solid cash position (over $2 per share in net cash) provides sufficient financial flexibility. A good insider rating (recent CEO and 30% owner buys with no sells) is also encouraging.